


# Rolapitant in the Current Management of Chemotherapy-induced Nausea and Vomiting

Bernardo Rapoport,<sup>1,2</sup> Pere Gascon,<sup>3</sup> Florian Scotte,<sup>3</sup> Karin Jordan,<sup>4</sup> Massimo Di Maio,<sup>5</sup> Sussanne Borjeson<sup>6</sup> and Sam H Ahmedzai<sup>6</sup>

1. The Medical Oncology Centre of Rosebank, Johannesburg, South Africa; 2. Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa; 3. Department of Medical Oncology and Supportive Care, Foch Hospital, Suresnes, France; 4. Department of Medicine V, Haematology, Oncology and Rheumatology, University of Heidelberg, Germany; 5. Department of Oncology, University of Turin, Ordine Maurizio Hospital, Turin, Italy; 6. The University of Sheffield, NIHR National Speciality Lead for Cancer, Sheffield, UK



**Citation:** *European Oncology & Haematology*. 2018;14(1):[Online only]  
**Erratum to:** *European Oncology & Haematology*. 2017;13(2):120–6  
DOI: <https://doi.org/10.17925/EOH.2017.13.02.120>

The authors of the aforementioned article would like to make revisions to the labels in *Figure 1* as shown below. The article has been corrected online. □

